Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 3
1984 9
1985 9
1986 10
1987 10
1988 5
1989 6
1990 5
1991 4
1992 10
1993 7
1994 3
1995 9
1996 6
1997 12
1998 14
1999 5
2000 7
2001 11
2002 15
2003 15
2004 14
2005 13
2006 10
2007 8
2008 27
2009 15
2010 17
2011 20
2012 13
2013 19
2014 11
2015 14
2016 3
2017 2
2018 2
2019 3
2020 4
2021 3
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

358 results

Results by year

Filters applied: . Clear all
Page 1
Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial.
Dinh A, Ropers J, Duran C, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Makhloufi S, Mellon G, de Lastours V, Bouchand F, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Renaud B, Perronne C, Claessens YE, Labarère J, Bedos JP, Aegerter P, Crémieux AC; Pneumonia Short Treatment (PTC) Study Group. Dinh A, et al. Lancet. 2021 Mar 27;397(10280):1195-1203. doi: 10.1016/S0140-6736(21)00313-5. Lancet. 2021. PMID: 33773631 Clinical Trial.
Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
Bachelard A, Le Hingrat Q, Ferré VM, Lê M, Peytavin G, Damond F, Charpentier C, Fremont Goudot G, Goupil de Bouille J, Lariven S, Delobel P, Yazdanpanah Y, Descamps D, Matheron S, Ghosn J; ANRS CO05 VIH-2 cohort study group. Bachelard A, et al. Clin Infect Dis. 2024 Apr 10;78(4):1005-1010. doi: 10.1093/cid/ciad695. Clin Infect Dis. 2024. PMID: 38630945
Exclusive oral antibiotic treatment for hospitalized community-acquired pneumonia: a post-hoc analysis of a randomized clinical trial.
Dinh A, Duran C, Ropers J, Bouchand F, Deconinck L, Matt M, Senard O, Lagrange A, Mellon G, Calin R, Makhloufi S, de Lastours V, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Renaud B, Claessens YE, Labarère J, Bedos JP, Aegerter P, Crémieux AC; Pneumonia short treatment (PTC) study group. Dinh A, et al. Clin Microbiol Infect. 2024 Aug;30(8):1020-1028. doi: 10.1016/j.cmi.2024.05.003. Epub 2024 May 9. Clin Microbiol Infect. 2024. PMID: 38734138 Clinical Trial.
Drug resistance mutations in HIV-1.
Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD; International AIDS Society-USA Drug Resistance Mutations Group. Johnson VA, et al. Among authors: brun vezinet f. Top HIV Med. 2003 Nov-Dec;11(6):215-21. Top HIV Med. 2003. PMID: 14724329 Review.
Update on the human immunodeficiency virus.
Brun-Vézinet F, Charpentier C. Brun-Vézinet F, et al. Med Mal Infect. 2013 May;43(5):177-84. doi: 10.1016/j.medmal.2013.03.001. Epub 2013 Apr 28. Med Mal Infect. 2013. PMID: 23628423 Review.
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trial.
Eholie SP, Ekouevi DK, Chazallon C, Charpentier C, Messou E, Diallo Z, Zoungrana J, Minga A, Ngom Gueye NF, Hawerlander D, Dembele F, Colin G, Tchounga B, Karcher S, Le Carrou J, Tchabert-Guié A, Toni TD, Ouédraogo AS, Bado G, Toure Kane C, Seydi M, Poda A, Mensah E, Diallo I, Drabo YJ, Anglaret X, Brun-Vezinet F; FIT-2 study group. Eholie SP, et al. Among authors: brun vezinet f. Lancet HIV. 2024 Jun;11(6):e380-e388. doi: 10.1016/S2352-3018(24)00085-7. Epub 2024 May 10. Lancet HIV. 2024. PMID: 38740027 Free article. Clinical Trial.
[HIV genetic diversity and its consequences].
Roquebert B, Damond F, Brun-Vézinet F, Descamps D. Roquebert B, et al. Among authors: brun vezinet f. Pathol Biol (Paris). 2009 Mar;57(2):142-8. doi: 10.1016/j.patbio.2008.04.004. Epub 2008 Jun 3. Pathol Biol (Paris). 2009. PMID: 18511216 Review. French.
HIV-1 diversity in Romania.
Apetrei C, Necula A, Holm-Hansen C, Loussert-Ajaka I, Pandrea I, Cozmei C, Streinu-Cercel A, Pascu FR, Negut E, Molnar G, Duca M, Pecec M, Brun-Vézinet F, Simon F. Apetrei C, et al. Among authors: brun vezinet f. AIDS. 1998 Jun 18;12(9):1079-85. AIDS. 1998. PMID: 9662205
Tropism distribution among antiretroviral-naive HIV-2-infected patients.
Visseaux B, Charpentier C, Ozanne A, Nizard A, Drumard S, Fagard C, Glohi D, Damond F, Brun-Vézinet F, Matheron S, Descamps D; ANRS CO5 HIV-2 Cohort. Visseaux B, et al. Among authors: brun vezinet f. AIDS. 2015 Oct 23;29(16):2209-12. doi: 10.1097/QAD.0000000000000825. AIDS. 2015. PMID: 26544584
Epidemiology of HIV-2 infection.
De Cock KM, Brun-Vézinet F. De Cock KM, et al. Among authors: brun vezinet f. AIDS. 1989;3 Suppl 1:S89-95. doi: 10.1097/00002030-198901001-00013. AIDS. 1989. PMID: 2514761 Review. No abstract available.
358 results